

Zydus receives final approval from the USFDA for Nystatin and Triamcinolone Acetonide Ointment USP

Ahmedabad, 12 November, 2018

Zydus Cadila has received the final approval from the USFDA to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD – Mycolog®-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.

The group now has 226 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
